SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-21-000019
Filing Date
2021-04-07
Accepted
2021-04-07 13:08:26
Documents
8
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 6-K form6ktemplate1.htm 6-K 19182
2 EX-99.1 oncycircular-march262021.htm EX-99.1 487735
3 EX-99.2 oncolytics-proxydraft.htm EX-99.2 9104
4 image_01.jpg GRAPHIC 74787
5 image_41.jpg GRAPHIC 117776
6 GRAPHIC oncolytics-proxydraft001.jpg GRAPHIC 142459
7 GRAPHIC oncolytics-proxydraft002.jpg GRAPHIC 218911
8 picture13.jpg GRAPHIC 13231
  Complete submission text file 0001129928-21-000019.txt   1297786
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 21811543
SIC: 2834 Pharmaceutical Preparations